Mutations

APOE c.-647A>G (rs439382)

Other Names: rs439382

Overview

Clinical Phenotype: Alzheimer's Disease
Position: (GRCh38/hg38):Chr19:44905218 A>G
Position: (GRCh37/hg19):Chr19:45408475 A>G
Transcript: NM_000041; ENSG00000130203
dbSNP ID: rs439382
Coding/Non-Coding: Non-Coding
DNA Change: Substitution
Reference Isoform: APOE Isoform 1
Genomic Region: 2kb upstream

Findings

This variant is associated with Alzheimer’s disease (AD) in African Americans, but at least in one study, the association did not survive adjustment for APOE4 and APOE2. The first study included participants from the AD Genetics Consortium (Reitz et al., 2013) and was reported in the database of the National Institute on Aging Genetics of Alzheimer’s Disease Data Storage Site (NIAGADS) (p=1.6x10-16; Oct 2022). A subsequent study, reported in a preprint, involved participants in the Alzheimer's Disease Sequencing Project (p=1.72x10-12; Lee et al., 2023, suppl table 4). This latter study noted that the association was not found when adjusting for the common APOE alleles (cut-off p<5x10-8) .

c.-647A>G was also reported in a small study in which the APOE genes of 257 Southern Chinese individuals—including 69 AD patients, 83 subjects with mild cognitive impairment (MCI), and 105 cognitively healthy controls—were sequenced (Yee et al., 2021). The variant was found in one AD patient (0.7%), two MCI patients (1.2%), and one control (0.5%). 

In the gnomAD variant database, the variant was reported at a frequency of 0.028 (gnomAD v2.1.1, Oct 2022). The frequency was higher (0.094) in individuals of African ancestry.

Biological Effect

The biological effect of this variant is unknown, but it is within the APOE promoter region (Paik et al., 1988) and, more specifically, in the HuD functional domain which spans nucleotides -651 to -366 (Maloney et al., 2007). In an in vitro reporter assay, HuD was shown to act as a negative regulatory element in multiple cell types, including neuronal-like rat chromaffin cells (PC12), SK-N-SH neuroblastoma cells, C6 glial cells, and U373 astroctyoma cells. However, the variant's 0.45 PHRED-scaled CADD score, which integrates diverse information in silico, was well below the commonly used threshold of 20 to predict deleteriousness (CADD v.1.6, Oct 2022).

Last Updated: 17 Nov 2023

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

References

Paper Citations

  1. . Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ4,and the risk of late-onset Alzheimer disease in African Americans. JAMA. 2013 Apr 10;309(14):1483-92. PubMed.
  2. . Association of Common and Rare Variants with Alzheimer's Disease in over 13,000 Diverse Individuals with Whole-Genome Sequencing from the Alzheimer's Disease Sequencing Project. 2023 Sep 02 10.1101/2023.09.01.23294953 (version 1) medRxiv.
  3. . Apolipoprotein E Gene Revisited: Contribution of Rare Variants to Alzheimer's Disease Susceptibility in Southern Chinese. Curr Alzheimer Res. 2021 Mar 24; PubMed.
  4. . Identification and characterization of transcriptional regulatory regions associated with expression of the human apolipoprotein E gene. J Biol Chem. 1988 Sep 15;263(26):13340-9. PubMed.
  5. . Important differences between human and mouse APOE gene promoters: limitation of mouse APOE model in studying Alzheimer's disease. J Neurochem. 2007 Nov;103(3):1237-57. PubMed.

Further Reading

No Available Further Reading

Protein Diagram

Primary Papers

  1. . Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ4,and the risk of late-onset Alzheimer disease in African Americans. JAMA. 2013 Apr 10;309(14):1483-92. PubMed.

Disclaimer: Alzforum does not provide medical advice. The Content is for informational, educational, research and reference purposes only and is not intended to substitute for professional medical advice, diagnosis or treatment. Always seek advice from a qualified physician or health care professional about any medical concern, and do not disregard professional medical advice because of anything you may read on Alzforum.